After talking with Teva Pharmaceutical (NYSE:TEVA) management, Mizuho analyst Irina Rivkind Koffler is more positive on the rebounding Israeli pharma giant in the midst of corporate restructuring plans that bode well for delaying a credit downgrade.
Story Continues
